Stonebridge Financial Group (Pennsylvania)’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$251K Buy
4,350
+53
+1% +$3.04K 0.02% 242
2026
Q1
$261K Sell
4,297
-687
-14% -$40K 0.02% 226
2025
Q4
$269K Sell
4,984
-3,567
-42% -$172K 0.02% 212
2025
Q3
$386K Sell
8,551
-622
-7% -$29K 0.03% 180
2025
Q2
$425K Sell
9,173
-19
-0.2% -$933 0.04% 168
2025
Q1
$561K Sell
9,192
-647
-7% -$37.7K 0.06% 137
2024
Q4
$556K Buy
+9,839
New +$550K 0.06% 141

Other funds holding BMY

Stonebridge Financial Group (Pennsylvania)'s BMY Position: Q2 2026 in Review

Stonebridge Financial Group (Pennsylvania) increased its Bristol-Myers Squibb (BMY) stake by 1.2% in Q2 2026, buying an estimated $3.04K and bringing the position to 4,350 shares worth $251K. The position accounts for 0.02% of the portfolio, ranked #242.

Stonebridge Financial Group (Pennsylvania) first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $561K in Q1 2025. 2,147 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Stonebridge Financial Group (Pennsylvania) held 4,350 shares of Bristol-Myers Squibb worth $251K as of Q2 2026.
  • Stonebridge Financial Group (Pennsylvania) bought 53 Bristol-Myers Squibb shares in Q2 2026, an estimated $3.04K.
  • Bristol-Myers Squibb made up 0.02% of Stonebridge Financial Group (Pennsylvania)'s portfolio in Q2 2026, its #242 holding.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
  • Stonebridge Financial Group (Pennsylvania)'s Bristol-Myers Squibb position peaked at $561K in Q1 2025.
  • 2,147 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2026, filed 6 Jul 2026.